Cancer cell-derived EVs activate mast cells through CD73-mediated adenosine signaling, leading to the upregulation of pro-angiogenic and tissue remodeling factors, which contribute to an immunosuppressive TME (56). The gene discussed is NT5E; the disease is cancer.